07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: TRAF2 and NCK interacting kinase (TNIK)

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting TNIK could help treat colorectal cancer. In a human colorectal carcinoma cell line, the TNIK inhibitor NCB-0846 decreased tumor cell colony formation compared with...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: WAS protein family member 3 (WASF3); NCK associated protein 1 (NCKAP1); cytoplasmic FMR1 interacting protein 1 (CYFIP1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest that inhibiting the WASF3-NCKAP1- CYFIP1 complex could help treat metastatic breast cancer. In breast cancer patients, high tumor levels of NCKAP1 were associated...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colon cancer TRAF2 and NCK interacting kinase (TNIK) In vitro studies suggest that TNIK inhibitors could help treat colon cancer. In mouse small intestinal...
07:00 , Oct 29, 2009 |  BC Innovations  |  Targets & Mechanisms

Wnt it rains

For the second time in as many months, a research group has found a new target in the Wnt pathway that could be more druggable than previously identified components of the cancer-inducing signaling cascade. Antagonizing...